5 results about "Maculopathy" patented technology

The invention discloses a myopic maculopathy fundus color photo image classification method and system, and belongs to the technical field of image classification. Obtaining a to-be-analyzed fundus color photo; preprocessing the fundus color photo to extract an effective view area and reduce image acquisition difference interference; and inputting the preprocessed image into a deep learning classification network, and outputting an META-PM classification result corresponding to the myopic maculopathy. According to the method, on the premise of not depending on accurate focus labeling, the global structure and the local focus evidence are fused at the same time, the ordered level relation is explicitly modeled, and the cross-device robustness and the long-tail distribution adaptability are improved.

This invention discloses a method and system for grading myopic macular degeneration (ATN) based on multimodal medical imaging. The system includes an image acquisition module for acquiring multimodal retinal images to be graded; a preprocessing module for preprocessing the multimodal images to obtain image sequences that meet preset grading requirements; and a grading module for inputting the image sequences into a pre-stored multimodal multi-task grading model. The model performs feature extraction, multimodal fusion, and multi-task classification on the image sequences, outputting a lesion grade prediction result for each grading task. This invention significantly improves the model's sensitivity to pathological regions by performing pixel-level segmentation of the input images and locating key anatomical structures. In subsequent steps, spatial weighting is applied to CFP image modalities, and specific regions of OCT and OCTA are enhanced, effectively improving the accuracy and robustness of lesion diagnosis and localization.

The invention provides a nucleic acid molecule and application thereof, and belongs to the technical field of biology. Specifically, compared with SEQ ID NO: 1, the nucleic acid molecule has c.1850A > C mutation. The mutation is closely related to myopic maculopathy.

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and / or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.

The invention discloses application of a targeted stimulation molecule in preparation of a medicine for treating maculopathy, and relates to the field of biological medicine. The medicine provided by the invention can mediate the interaction between senescence cells and immune cells, enhance the endogenous immune function, and achieve the purposes of effectively removing senescence cells and improving senescence-related diseases. One end of the functional molecule for targeted senescence cell immune sensitization targets senescence cell membrane molecules, glutamic acid is marked on the surfaces of senescence cells, coupling between endogenous immune cells and the senescence cells is mediated, and adhesion and removal of the senescence cells by the immune cells are promoted. The molecule can regulate the immune microenvironment of aging tissues, effectively reduce the number of aging-related beta-galactosidase positive aging cells, and obviously improve the maculopathy condition at the same time.